CA2852843A1 - Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease - Google Patents

Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease Download PDF

Info

Publication number
CA2852843A1
CA2852843A1 CA2852843A CA2852843A CA2852843A1 CA 2852843 A1 CA2852843 A1 CA 2852843A1 CA 2852843 A CA2852843 A CA 2852843A CA 2852843 A CA2852843 A CA 2852843A CA 2852843 A1 CA2852843 A1 CA 2852843A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
cycloalkyl
aryl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2852843A
Other languages
English (en)
French (fr)
Inventor
Dirk Classen-Houben
Andrea Wolkerstorfer
Oliver Szolar
Mark Smith
Sung-Sau So
Stephen Cusack
Thierry Langer
Bruno Giethlen
Christophe Morice
Celine Michaut-Simon
Laurence JUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savira Pharmaceuticals GmbH, F Hoffmann La Roche AG, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Savira Pharmaceuticals GmbH
Publication of CA2852843A1 publication Critical patent/CA2852843A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2852843A 2011-10-21 2012-10-19 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease Abandoned CA2852843A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550057P 2011-10-21 2011-10-21
US61/550,057 2011-10-21
PCT/EP2012/070760 WO2013057253A1 (en) 2011-10-21 2012-10-19 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
CA2852843A1 true CA2852843A1 (en) 2013-04-25

Family

ID=47189887

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2852843A Abandoned CA2852843A1 (en) 2011-10-21 2012-10-19 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Country Status (11)

Country Link
US (2) US20130102601A1 (enExample)
EP (1) EP2794616B1 (enExample)
JP (1) JP6033873B2 (enExample)
KR (1) KR20140097197A (enExample)
CN (1) CN103958521B (enExample)
BR (1) BR112014008412A2 (enExample)
CA (1) CA2852843A1 (enExample)
ES (1) ES2589459T3 (enExample)
MX (1) MX342176B (enExample)
RU (1) RU2014120477A (enExample)
WO (1) WO2013057253A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
US10081616B2 (en) * 2014-08-28 2018-09-25 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
ES2857906T3 (es) 2015-04-28 2021-09-29 Shionogi & Co Derivado de piridona policíclica contra la influenza y profármaco del mismo
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
SG10201911957QA (en) 2015-12-15 2020-02-27 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
CN109415345B (zh) 2016-06-29 2022-01-11 豪夫迈·罗氏有限公司 基于哒嗪酮的广谱抗流感抑制剂
EP4458348A3 (en) 2016-08-10 2025-01-29 Shionogi & Co., Ltd Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
CA3069990A1 (en) 2017-08-01 2019-02-07 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
CN116096725A (zh) * 2020-04-08 2023-05-09 雷密克斯医疗公司 用于调节剪接的化合物和方法
CN116997555A (zh) * 2021-03-17 2023-11-03 豪夫迈·罗氏有限公司 新颖噻吩并嘧啶酮衍生物
US11932656B1 (en) 2023-10-06 2024-03-19 King Faisal University Thieno[2,3-d]pyrimidines as COX-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
KR100714519B1 (ko) * 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
ES2564422T3 (es) * 2007-11-15 2016-03-22 Ym Biosciences Australia Pty Ltd Compuestos heterocíclicos que contienen N
ES2665277T3 (es) 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Also Published As

Publication number Publication date
US20130102601A1 (en) 2013-04-25
ES2589459T3 (es) 2016-11-14
MX342176B (es) 2016-09-20
BR112014008412A2 (pt) 2017-04-11
CN103958521A (zh) 2014-07-30
KR20140097197A (ko) 2014-08-06
CN103958521B (zh) 2016-10-19
HK1199881A1 (en) 2015-07-24
JP6033873B2 (ja) 2016-11-30
EP2794616A1 (en) 2014-10-29
WO2013057253A1 (en) 2013-04-25
JP2014530838A (ja) 2014-11-20
MX2014003801A (es) 2015-03-11
US20160376286A1 (en) 2016-12-29
EP2794616B1 (en) 2016-06-29
RU2014120477A (ru) 2015-11-27

Similar Documents

Publication Publication Date Title
CA2852843A1 (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8921388B2 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CA2852750A1 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2864338B1 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CA2894452A1 (en) Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
CA2874253A1 (en) 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
AU2015298876A1 (en) Indoles for use in influenza virus infection
EP2945945B1 (en) Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20170081331A1 (en) Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
HK1199881B (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20181019